This product has recently been released.
This product is freeze dried. All water molecules have been removed.
This antibody is shipped with its antigen FREE of charge!
- Peptide (C)EELLLDGWGEPPDPE, corresponding to amino acid residues 20-34 of rat CRHR2 (Accession P47866). Extracellular, N-terminus.
- Western blot analysis of mouse brain membrane (lanes 1 and 5), rat cerebellum (lanes 2 and 6), rat lung (lanes 3 and 7) and rat kidney (lanes 4 and 8) lysates:1-4. Anti-CRF2/CRHR2 (extracellular) Antibody (#ACR-052), (1:200).
5-8. Anti-CRF2/CRHR2 (extracellular) Antibody, preincubated with the negative control antigen.Western blot analysis of MOLT-4 (lanes 1 and 5), CAKI-1 (lanes 2 and 6), MEG-O1 (lanes 3 and 7) and COLO-205 (lanes 4 and 8) cell line lysates:1-4. Anti-CRF2/CRHR2 (extracellular) Antibody (#ACR-052), (1:200).
5-8. Anti-CRF2/CRHR2 (extracellular) Antibody, preincubated with the negative control antigen.
- Cell surface detection of Corticotropin-releasing factor receptor 2 in live intact HL-60 (human promyelocytic leukemia) cells:___ Cells.
___ Cells + FITC-conjugated goat anti-rabbit antibody.
___ Cells + Anti-CRF2/CRHR2 (extracellular) Antibody (#ACR-052) (5 µg /5x105 cells) +FITC-conjugated goat anti-rabbit antibody.
- 1. Pal, K. et al. (2010) J. Biol. Chem. 285, 40351.
- 2. Fekete, E.M. and Zorrilla, E.P. (2007) Front. Neuroendocrinol. 28, 1.
- 3. Bale, T.L. et al. (2003) Trends Cardiovasc. 13, 68.
- 4. Yang, L.Z. et al. (2010) Eur. J. Pharmacol. 632, 1.
- 5. Dieterle, T. et al. (2009) Hypertension 53, 739.
- 6. Hillhouse, E.W. and Grammatopoulos, D.K. (2006) Endocr. Rev. 27, 260.
CRFR2 is a G-protein coupled receptor for CRF (corticotropin-releasing factor) and urocortins UCN1, UCN2, and UCN3. The receptor-ligand interaction causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and down-stream effectors, such as adenylate cyclase, leading to increased intracellular cAMP levels1.
CRFR2 is expressed in the CNS and peripheral tissues including the heart, vasculature, skeletal muscle, and gastrointestinal tract, and it plays a central role in coordinating endocrine, autonomic, and behavioral responses to stress1. CRFR2 ligands, the UCN peptides, exert actions in central and peripheral tissues where they modulate cardiovascular, immune, gastrointestinal, and reproductive functions in response to stress2. UCNs can also affect tumor biology as a consequence of the CRFR2 role as a suppressor of vascularization3.
The involvement of CRF/UCN family peptides and their receptors in diverse pathophysiological states has generated intense interest in developing therapeutic agents that selectively target the receptors. CRFR2-selective agonists have the potential to treat heart failure4, hypertension5 and other disorders.
CRFR2 shares 68% amino acid sequence identity with another CRF receptor, CRFR1. Both of the receptors have a bipartite domain structure consisting of an N-terminal extracellular domain (ECD) of about 100–150 amino acids linked to a 7-transmembrane helical bundle domain embedded in the plasma membrane. Peptide binding spans the two domains, with the C-terminal portion of the peptide binding to the ECD to impart high affinity and the N-terminal portion binding to the 7-transmembrane domain to activate the receptor6.
CRFR2 has three functional full-length isoforms, α, β, and γ, that differ only at the extreme N-terminus of the receptor. In humans, the CRFR2β isoform is expressed in the brain, and the CRFR2α isoform predominates in the periphery6.
Species reactivity key:
Anti-CRF2/CRHR2 (extracellular) Antibody (#ACR-052) is a highly specific antibody directed against an epitope of the rat Corticotropin-releasing factor receptor 2. The antibody can be used in western blot and indirect live cell flow cytometry applications. It has been designed to recognize CRHR2 from rat, mouse, and human samples.